Posted by Michael Wonder on 18 Feb 2017
Will drug companies' price-transparency efforts fall short?
16 February 2017 - In January, 2017, Merck disclosed its aggregate drug price increases since 2010 in an annual Corporate Responsibility Report and has pledged to update those figures each year.
Despite headlines and widespread outrage about massive price hikes in the industry in recent years, Merck's disclosures show a track record of responsible pricing, according to Adam Schechter (Global Human Health, Merck & Co, Philadelphia, PA, USA). The company's disclosed figures indicate that list price hikes for its entire portfolio averaged 9·4% annually between 2010 and 2016, peaking at 10·5% in 2014.
